Chembio Diagnostics Stock | CEMI | US1635722093 | A1JY4D

Date	Chembio Diagnostics Price
4/27/2023	0.46 undefined
4/26/2023	0.45 undefined

Date	Chembio Diagnostics Revenue	Chembio Diagnostics EBIT	Chembio Diagnostics Net Income
2025e	35.78 M undefined	-19.9 M undefined	-34.8 M undefined
2024e	36.92 M undefined	-26.38 M undefined	-40.29 M undefined
2023e	38.86 M undefined	-35.67 M undefined	-47.57 M undefined
2022	49.52 M undefined	-20.4 M undefined	-23.29 M undefined
2021	47.82 M undefined	-24.01 M undefined	-33.9 M undefined
2020	32.47 M undefined	-21.95 M undefined	-25.52 M undefined
2019	34.46 M undefined	-12.61 M undefined	-13.68 M undefined
2018	34.58 M undefined	-7.64 M undefined	-7.87 M undefined
2017	24.02 M undefined	-6.45 M undefined	-6.37 M undefined
2016	17.87 M undefined	-7.57 M undefined	-13.35 M undefined
2015	24.26 M undefined	-3.55 M undefined	-2.4 M undefined
2014	27.65 M undefined	-1.55 M undefined	-1.14 M undefined
2013	29.55 M undefined	1 M undefined	530,000 undefined
2012	25.61 M undefined	1.45 M undefined	940,000 undefined
2011	19.39 M undefined	1.09 M undefined	6.21 M undefined
2010	16.7 M undefined	2.57 M undefined	2.51 M undefined
2009	13.83 M undefined	320,000 undefined	310,000 undefined
2008	11.05 M undefined	-2.07 M undefined	-1.95 M undefined
2007	9.23 M undefined	-2.88 M undefined	-8.27 M undefined
2006	6.5 M undefined	-4.58 M undefined	-8.21 M undefined
2005	3.94 M undefined	-3.3 M undefined	-6.77 M undefined
2004	3.31 M undefined	-3.11 M undefined	-5.04 M undefined
2003	0 undefined	-10,000 undefined	0 undefined

	Revenue	EBIT	Net Income
2003	0 USD	-10,000 USD	0 USD
2004	3.31 M USD	-3.11 M USD	-5.04 M USD
2005	3.94 M USD	-3.3 M USD	-6.77 M USD
2006	6.5 M USD	-4.58 M USD	-8.21 M USD
2007	9.23 M USD	-2.88 M USD	-8.27 M USD
2008	11.05 M USD	-2.07 M USD	-1.95 M USD
2009	13.83 M USD	320,000 USD	310,000 USD
2010	16.7 M USD	2.57 M USD	2.51 M USD
2011	19.39 M USD	1.09 M USD	6.21 M USD
2012	25.61 M USD	1.45 M USD	940,000 USD
2013	29.55 M USD	1 M USD	530,000 USD
2014	27.65 M USD	-1.55 M USD	-1.14 M USD
2015	24.26 M USD	-3.55 M USD	-2.4 M USD
2016	17.87 M USD	-7.57 M USD	-13.35 M USD
2017	24.02 M USD	-6.45 M USD	-6.37 M USD
2018	34.58 M USD	-7.64 M USD	-7.87 M USD
2019	34.46 M USD	-12.61 M USD	-13.68 M USD
2020	32.47 M USD	-21.95 M USD	-25.52 M USD
2021	47.82 M USD	-24.01 M USD	-33.9 M USD
2022	49.52 M USD	-20.4 M USD	-23.29 M USD
2023e	38.86 M USD	-35.67 M USD	-47.57 M USD
2024e	36.92 M USD	-26.38 M USD	-40.29 M USD
2025e	35.78 M USD	-19.9 M USD	-34.8 M USD

2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022

0	0.04	0.23	4.29	2.83	1.21	1.07	2.14	3.01	2.95	9.65	4.61	5.38	10.55	3.79	12.52	18.27	23.07	28.77	18.18
0	0.17	1.26	1.35	0.95	0.81	1.78	3.95	3	4.82	4.59	8.34	2.42	3.38	2.09	7.37	3.66	3.38	11.44	6.54
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	12.19
0	0.54	0.69	1.11	1.45	1.82	1.56	1.35	2.3	2.49	3.19	3.64	3.58	3.34	4.42	7.85	9.6	12.52	12.92	7.72
0	0.47	0.29	0.2	0.24	0.23	0.27	0.2	0.68	0.75	1.1	1.07	1.26	0.84	0.55	0.7	0.69	0.78	2.1	3.83
0	1.22	2.47	6.95	5.47	4.07	4.68	7.64	8.99	11.01	18.53	17.66	12.64	18.11	10.85	28.44	32.22	39.75	55.23	48.45
0	0.19	0.44	0.6	0.83	0.88	0.57	0.81	1.06	1.43	1.98	2.8	2.37	1.71	1.91	2.87	13.17	15.03	14.64	13.72
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0.26	0.94	0.7	0.6	0.5	0.4	0.33	0.26	0.1	0	1.6	3.88	3.91	3.65	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.67	4.98	5.87	5.96	3.02	0
0	0.03	0.11	0.35	0.03	0.03	0.38	0.04	4.93	4.5	3.65	4.3	5.71	0.75	0.59	0.72	0.54	0.51	0.36	0.43
0	0.22	0.55	0.95	1.12	1.85	1.65	1.45	6.49	6.33	5.96	7.36	8.18	2.46	5.77	12.45	23.49	25.15	18.02	14.16
0	1.44	3.02	7.9	6.59	5.92	6.33	9.09	15.48	17.34	24.49	25.02	20.82	20.57	16.62	40.89	55.71	64.9	73.25	62.61

0.18	2.5	5.89	12.72	0.61	0.62	0.62	0.62	0.08	0.08	0.09	0.1	0.1	0.12	0.12	0.17	0.18	0.2	0.3	0.37
0.19	9.08	14.03	19.96	39	39.25	39.45	39.66	40.68	41.12	46.88	47.56	47.89	60.72	62.82	90.95	95.43	124.96	165.77	172.28
-0.37	-12.1	-18.87	-27.07	-35.35	-37.29	-36.99	-34.47	-28.26	-27.32	-26.79	-27.93	-30.33	-43.67	-50.04	-57.91	-71.59	-97.11	-131.01	-154.3
0	0	0	0	0	0	0	0	0	0	0	0	0	0	180	110	10	-90	-592.37	-337.29
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	-0.52	1.05	5.61	4.26	2.58	3.08	5.81	12.5	13.88	20.18	19.73	17.66	17.17	13.08	33.32	24.03	27.96	34.47	18
0	1.1	1.48	1.71	2.18	2.38	0.66	0.88	1.26	1.69	1.82	1.98	1.26	1.44	1.49	3.62	3.14	5.73	7.75	3.34
0	0.18	0.12	0.09	0	0	1.24	1.17	1.53	1.62	2.49	2.97	1.54	1.58	1.55	2.27	2.95	4.96	6.27	17.3
0	0.28	0.18	0	0.04	0	1.24	0.94	0	0.02	0	0.34	0.35	0.39	0.05	0.42	0.13	1.61	0	0
0	50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0.05	0.04	0.04	0.02	0.02	0.03	0.08	0.07	0.05	0	0	0	0	0	0.21	0.22	0.06	1.27	18.65
0	1.66	1.82	1.84	2.24	2.4	3.17	3.07	2.86	3.38	4.31	5.29	3.15	3.41	3.09	6.52	6.44	12.36	15.28	39.3
0	0.07	0.04	0.01	0.08	0.06	0.05	0.2	0.13	0.08	0	0	0	0	0.1	0.17	17.82	18.37	17.73	0.09
0	0	0	0	0	0	0	0	0	0	0	0	0	0	340	890	470	70	0	0
0	0.21	0.1	0.45	0	0.88	0	0	0	0	0	0	0	0	0	0	6.97	6.33	5.98	5.43
0	0.28	0.14	0.46	0.08	0.94	0.05	0.2	0.13	0.08	0	0	0	0	0.44	1.06	25.26	24.77	23.7	5.51
0	1.94	1.96	2.3	2.32	3.34	3.22	3.27	2.99	3.46	4.31	5.29	3.15	3.41	3.53	7.58	31.7	37.13	38.99	44.81
0	1.42	3.01	7.91	6.58	5.92	6.3	9.08	15.49	17.34	24.49	25.02	20.81	20.58	16.61	40.9	55.73	65.09	73.46	62.82

2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
0	-3	-3	-5	-2	-1	0	2	6	0	0	-1	-2	-13	-6	-7	-13	-25	-33	-23
0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	1	2	2	2
0	0	0	0	0	0	0	0	-5	0	0	0	-1	5	0	0	0	0	0	0
0	0	0	0	0	0	0	-1	0	-1	0	-3	3	0	0	-5	1	2	-8	2
0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	1	8	5
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	-2	-4	-4	-1	-1	0	1	2	0	2	-3	1	-6	-5	-11	-9	-18	-30	-12
0	0	0	0	0	0	0	0	0	0	0	-1	-1	0	-1	-1	-3	-4	-1	-1
0	0	0	0	0	0	0	0	0	0	0	-1	-1	0	-1	-6	-3	-4	-1	-1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-5	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	18	0	0	0
0	1	4	8	0	0	0	0	0	0	5	0	0	12	0	27	0	28	38	4
0	2	4	8	0	0	0	0	0	0	5	0	0	12	0	27	18	27	38	3
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	4	-1	-1	0	1	0	0	6	-5	0	5	-6	8	5	4	5	-10
0	-2.71	-4.35	-4.58	-1.76	-1.59	-0.14	0.84	1.54	-0.11	1.39	-5.27	0.76	-6.82	-6.06	-13.25	-12.86	-23.06	-32.74	-14.15
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Chembio Diagnostics Gross margin	Chembio Diagnostics Profit margin	Chembio Diagnostics EBIT margin	Chembio Diagnostics Profit margin
2025e	22.1 %	-55.62 %	-97.26 %
2024e	22.1 %	-71.46 %	-109.12 %
2023e	22.1 %	-91.8 %	-122.44 %
2022	22.1 %	-41.2 %	-47.03 %
2021	27.86 %	-50.2 %	-70.9 %
2020	26.49 %	-67.6 %	-78.6 %
2019	35.03 %	-36.59 %	-39.7 %
2018	34.64 %	-22.09 %	-22.76 %
2017	46.17 %	-26.85 %	-26.52 %
2016	47.29 %	-42.36 %	-74.71 %
2015	43.24 %	-14.63 %	-9.89 %
2014	39.1 %	-5.61 %	-4.12 %
2013	41.62 %	3.38 %	1.79 %
2012	42.13 %	5.66 %	3.67 %
2011	48.43 %	5.62 %	32.03 %
2010	48.5 %	15.39 %	15.03 %
2009	42.37 %	2.31 %	2.24 %
2008	34.84 %	-18.73 %	-17.65 %
2007	30.34 %	-31.2 %	-89.6 %
2006	24.77 %	-70.46 %	-126.31 %
2005	33.76 %	-83.76 %	-171.83 %
2004	21.15 %	-93.96 %	-152.27 %
2003	22.1 %	0 %	0 %

	Gross margin	EBIT margin	Profit margin
2003	22.1 %	0 %	0 %
2004	21.15 %	-93.96 %	-152.27 %
2005	33.76 %	-83.76 %	-171.83 %
2006	24.77 %	-70.46 %	-126.31 %
2007	30.34 %	-31.2 %	-89.6 %
2008	34.84 %	-18.73 %	-17.65 %
2009	42.37 %	2.31 %	2.24 %
2010	48.5 %	15.39 %	15.03 %
2011	48.43 %	5.62 %	32.03 %
2012	42.13 %	5.66 %	3.67 %
2013	41.62 %	3.38 %	1.79 %
2014	39.1 %	-5.61 %	-4.12 %
2015	43.24 %	-14.63 %	-9.89 %
2016	47.29 %	-42.36 %	-74.71 %
2017	46.17 %	-26.85 %	-26.52 %
2018	34.64 %	-22.09 %	-22.76 %
2019	35.03 %	-36.59 %	-39.7 %
2020	26.49 %	-67.6 %	-78.6 %
2021	27.86 %	-50.2 %	-70.9 %
2022	22.1 %	-41.2 %	-47.03 %
2023e	22.1 %	-91.8 %	-122.44 %
2024e	22.1 %	-71.46 %	-109.12 %
2025e	22.1 %	-55.62 %	-97.26 %

Date	Chembio Diagnostics Sales per Share	Chembio Diagnostics EBIT per share	Chembio Diagnostics Earnings per Share
2025e	0.97 undefined	0 undefined	-0.95 undefined
2024e	1.01 undefined	0 undefined	-1.1 undefined
2023e	1.06 undefined	0 undefined	-1.3 undefined
2022	1.53 undefined	-0.63 undefined	-0.72 undefined
2021	1.97 undefined	-0.99 undefined	-1.4 undefined
2020	1.7 undefined	-1.15 undefined	-1.34 undefined
2019	2.03 undefined	-0.74 undefined	-0.81 undefined
2018	2.4 undefined	-0.53 undefined	-0.55 undefined
2017	1.95 undefined	-0.52 undefined	-0.52 undefined
2016	1.68 undefined	-0.71 undefined	-1.26 undefined
2015	2.52 undefined	-0.37 undefined	-0.25 undefined
2014	2.9 undefined	-0.16 undefined	-0.12 undefined
2013	3.1 undefined	0.11 undefined	0.06 undefined
2012	2.97 undefined	0.17 undefined	0.11 undefined
2011	2.27 undefined	0.13 undefined	0.73 undefined
2010	1.88 undefined	0.29 undefined	0.28 undefined
2009	1.47 undefined	0.03 undefined	0.03 undefined
2008	1.44 undefined	-0.27 undefined	-0.25 undefined
2007	5.04 undefined	-1.57 undefined	-4.52 undefined
2006	5.04 undefined	-3.55 undefined	-6.36 undefined
2005	4.1 undefined	-3.44 undefined	-7.05 undefined
2004	4.41 undefined	-4.15 undefined	-6.72 undefined
2003	0 undefined	-0 undefined	0 undefined

	Sales per Share	EBIT per share	Earnings per Share
2003	0 USD	-0 USD	0 USD
2004	4.41 USD	-4.15 USD	-6.72 USD
2005	4.1 USD	-3.44 USD	-7.05 USD
2006	5.04 USD	-3.55 USD	-6.36 USD
2007	5.04 USD	-1.57 USD	-4.52 USD
2008	1.44 USD	-0.27 USD	-0.25 USD
2009	1.47 USD	0.03 USD	0.03 USD
2010	1.88 USD	0.29 USD	0.28 USD
2011	2.27 USD	0.13 USD	0.73 USD
2012	2.97 USD	0.17 USD	0.11 USD
2013	3.1 USD	0.11 USD	0.06 USD
2014	2.9 USD	-0.16 USD	-0.12 USD
2015	2.52 USD	-0.37 USD	-0.25 USD
2016	1.68 USD	-0.71 USD	-1.26 USD
2017	1.95 USD	-0.52 USD	-0.52 USD
2018	2.4 USD	-0.53 USD	-0.55 USD
2019	2.03 USD	-0.74 USD	-0.81 USD
2020	1.7 USD	-1.15 USD	-1.34 USD
2021	1.97 USD	-0.99 USD	-1.4 USD
2022	1.53 USD	-0.63 USD	-0.72 USD
2023e	1.06 USD	0 USD	-1.3 USD
2024e	1.01 USD	0 USD	-1.1 USD
2025e	0.97 USD	0 USD	-0.95 USD

Segmente	2022	2021	2020	2019	2018
Net Product Sales	-	-	-	4.8 M U001	8.61 M U001
Revenue earned during the period from research and development and grants when earned	-	-	-	4.68 M U001	5.72 M U001
License and Royalty Revenue	-	-	-	938,753 U001	948,773 U001
Net Product Revenue	-	34.74 M U001	24.77 M U001	-	-
Net Product Sales	47.09 M U001	-	-	-	-
Government Grant Income	1.18 M U001	10.89 M U001	2.02 M U001	-	-
Revenue earned during the period from research and development milestones when those milestones are reached and non-milestone contracts and grants when earned	-	-	-	4.68 M U001	5.72 M U001
Revenue earned during the period from research and development	112,986 U001	1.16 M U001	4.85 M U001	-	-
License and Royalty Revenue	1.14 M U001	1.03 M U001	832,562 U001	-	-

	Net Product Sales	Revenue earned during the period from research and development and grants when earned	License and Royalty Revenue	Net Product Revenue	Net Product Sales	Government Grant Income	Revenue earned during the period from research and development milestones when those milestones are reached and non-milestone contracts and grants when earned	Revenue earned during the period from research and development	License and Royalty Revenue
2018	8.61 M USD	5.72 M USD	948,773 USD	0 USD	0 USD	0 USD	5.72 M USD	0 USD	0 USD
2019	4.8 M USD	4.68 M USD	938,753 USD	0 USD	0 USD	0 USD	4.68 M USD	0 USD	0 USD
2020	0 USD	0 USD	0 USD	24.77 M USD	0 USD	2.02 M USD	0 USD	4.85 M USD	832,562 USD
2021	0 USD	0 USD	0 USD	34.74 M USD	0 USD	10.89 M USD	0 USD	1.16 M USD	1.03 M USD
2022	0 USD	0 USD	0 USD	0 USD	47.09 M USD	1.18 M USD	0 USD	112,986 USD	1.14 M USD

Date	Africa	Asia	Continent of Europe and Region of Middle East	Latin America	United States
2022	7 M U001	665,159 U001	4.52 M U001	19.27 M U001	18.07 M U001
2021	5.56 M U001	664,579 U001	5.18 M U001	18.42 M U001	17.99 M U001
2020	4.89 M U001	824,488 U001	9.91 M U001	9.84 M U001	7.01 M U001
2019	7.56 M U001	888,800 U001	6.5 M U001	11.81 M U001	7.7 M U001
2018	8.61 M U001	1.39 M U001	2.17 M U001	11.72 M U001	2.85 M U001

	Africa	Asia	Continent of Europe and Region of Middle East	Latin America	United States
2018	8.61 M USD	1.39 M USD	2.17 M USD	11.72 M USD	2.85 M USD
2019	7.56 M USD	888,800 USD	6.5 M USD	11.81 M USD	7.7 M USD
2020	4.89 M USD	824,488 USD	9.91 M USD	9.84 M USD	7.01 M USD
2021	5.56 M USD	664,579 USD	5.18 M USD	18.42 M USD	17.99 M USD
2022	7 M USD	665,159 USD	4.52 M USD	19.27 M USD	18.07 M USD

	Number of stocks
2003	2.26 M Aktien
2004	750,000 Aktien
2005	960,000 Aktien
2006	1.29 M Aktien
2007	1.83 M Aktien
2008	7.66 M Aktien
2009	9.38 M Aktien
2010	8.87 M Aktien
2011	8.56 M Aktien
2012	8.61 M Aktien
2013	9.52 M Aktien
2014	9.53 M Aktien
2015	9.63 M Aktien
2016	10.62 M Aktien
2017	12.3 M Aktien
2018	14.43 M Aktien
2019	16.95 M Aktien
2020	19.09 M Aktien
2021	24.3 M Aktien
2022	32.27 M Aktien
2023e	32.27 M Aktien
2024e	32.27 M Aktien
2025e	32.27 M Aktien

Date	EPS Estimate	EPS Actual	Quarterly report
3/31/2022	-0.21	-0.29 (-35.39 %)	2022 Q1
12/31/2021	-0.21	-0.47 (-124.77 %)	2021 Q4
9/30/2021	-0.19	-0.24 (-23.84 %)	2021 Q3
6/30/2021	-0.37	-0.45 (-20.32 %)	2021 Q2
3/31/2021	-0.32	-0.22 (31.89 %)	2021 Q1
12/31/2020	-0.28	-0.35 (-24.03 %)	2020 Q4
9/30/2020	-0.27	-0.28 (-5.58 %)	2020 Q3
6/30/2020	-0.4	-0.4 (0.72 %)	2020 Q2
3/31/2020	-0.23	-0.25 (-7.71 %)	2020 Q1
12/31/2019	-0.25	-0.24 (3.96 %)	2019 Q4
9/30/2019	-0.17	-0.22 (-26.87 %)	2019 Q3
6/30/2019	-0.16	-0.19 (-22.11 %)	2019 Q2
3/31/2019	-0.16	-0.14 (9.68 %)	2019 Q1
12/31/2018	-0.17	-0.21 (-22.88 %)	2018 Q4
9/30/2018	-0.06	-0.16 (-161.44 %)	2018 Q3
6/30/2018	-0.07	-0.12 (-68.07 %)	2018 Q2
3/31/2018	-0.14	-0.05 (64.99 %)	2018 Q1
12/31/2017	-0.1	-0.16 (-56.86 %)	2017 Q4
9/30/2017	-0.11	-0.05 (55.44 %)	2017 Q3
6/30/2017	-0.17	-0.18 (-6.95 %)	2017 Q2
3/31/2017	-0.2	-0.13 (34.64 %)	2017 Q1
12/31/2016	-0.15	-0.21 (-37.25 %)	2016 Q4
9/30/2016	-0.17	-0.19 (-12.89 %)	2016 Q3
6/30/2016	-0.16	-0.86 (-443.96 %)	2016 Q2
3/31/2016	-0.09	-0.03 (67.32 %)	2016 Q1
12/31/2015	-0.09	-0.07 (19.26 %)	2015 Q4
9/30/2015	-0.07	-0.05 (29.97 %)	2015 Q3
6/30/2015	0	-0.07 (0 %)	2015 Q2
3/31/2015	-0.11	-0.07 (37.61 %)	2015 Q1
12/31/2014	-0.03	-0.05 (-63.4 %)	2014 Q4
9/30/2014	-0.02	-0.03 (-47.06 %)	2014 Q3
6/30/2014	-0.02	-0.02 (15.97 %)	2014 Q2
3/31/2014	-0.01	-0.02 (-96.08 %)	2014 Q1
12/31/2013	0.04	-0.03 (-167.87 %)	2013 Q4
9/30/2013	0.08	0.07 (-10.49 %)	2013 Q3
6/30/2013	-0.04	-0.03 (19.79 %)	2013 Q2
3/31/2013	0.02	0.04 (68.07 %)	2013 Q1
12/31/2012	0.05	0.06 (30.72 %)	2012 Q4
9/30/2012	0.04	-0.04 (-198.04 %)	2012 Q3
6/30/2012	0.03	0.04 (30.72 %)	2012 Q2
3/31/2012	0	0.08 (0 %)	2012 Q1
6/30/2011	0	0 (0 %)	2011 Q2
3/31/2011	0	0 (0 %)	2011 Q1
12/31/2010	0	0.24 (0 %)	2010 Q4
9/30/2010	0	0 (0 %)	2010 Q3
6/30/2010	-0.08	0.08 (198.04 %)	2010 Q2
9/30/2008	-0.08	0 (100 %)	2008 Q3
6/30/2008	-0.08	-0.08 (1.96 %)	2008 Q2
3/31/2008	-0.16	-0.08 (50.98 %)	2008 Q1
12/31/2007	-0.82	-2.56 (-213.73 %)	2007 Q4
9/30/2007	-0.98	-0.56 (42.81 %)	2007 Q3
3/31/2007	-1.06	-0.72 (32.13 %)	2007 Q1
12/31/2006	-0.98	-1.84 (-87.91 %)	2006 Q4

%	Name	Stocks	Change	Date
4.25169 %	The Vanguard Group, Inc.	1,561,470	-544	12/31/2022
0.76092 %	Geode Capital Management, L.L.C.	279,456	-656	12/31/2022
0.56094 %	BlackRock Institutional Trust Company, N.A.	206,009	-185	12/31/2022
0.37140 %	Renaissance Technologies LLC	136,400	22,800	12/31/2022
0.33504 %	BNY Mellon Asset Management	123,045	-907	12/31/2022
0.30292 %	Esfandiari (Javan)	111,251	12,903	3/28/2022
0.28987 %	Davis (Katherine Lyon)	106,457	16,314	3/28/2022
0.21952 %	Virtu Americas LLC	80,619	80,619	12/31/2022
0.18598 %	Northern Trust Investments, Inc.	68,304	0	12/31/2022
0.16337 %	Signaturefd, LLC	60,000	-9,300	12/31/2022
0.15485 %	Susquehanna International Group, LLP	56,869	56,869	12/31/2022
0.14727 %	Potthoff (John Gary Ph.D.)	54,086	16,314	3/28/2022
0.14543 %	State Street Global Advisors (US)	53,409	0	12/31/2022
0.13999 %	ValMark Advisers, Inc.	51,413	0	12/31/2022
0.13999 %	Eberly (Richard L)	51,413	0	3/28/2022
0.12499 %	Goldman (Neil A.)	45,903	0	3/28/2022
0.10194 %	Two Sigma Investments, LP	37,438	14,353	12/31/2022
0.07982 %	Group One Trading, L.P.	29,315	7,628	12/31/2022
0.05905 %	Jane Street Capital, L.L.C.	21,688	21,688	12/31/2022
0.05721 %	Hightower Advisors, LLC	21,012	0	12/31/2022
0.05689 %	Citadel Advisors LLC	20,895	-75,082	12/31/2022
0.05541 %	Newbridge Capital Management	20,350	0	12/31/2022
0.04857 %	Simplex Trading, LLC	17,836	9,467	12/31/2022
0.03768 %	Northern Trust Global Investments	13,839	0	12/31/2022
0.02723 %	Running Point Capital Advisors, LLC	10,000	0	12/31/2022
0.02678 %	Tower Research Capital LLC	9,834	-757	12/31/2022
0.02677 %	Freedom Wealth Alliance, LLC	9,831	9,831	12/31/2022
0.02147 %	Caso (Charles)	7,885	7,885	4/11/2022
0.02147 %	Angelico (Paul)	7,885	7,885	4/11/2022
0.01561 %	Bespalko (David William)	5,734	5,734	3/28/2022
0.01332 %	Acheson (David W. K.)	4,893	4,893	3/28/2022
0.00958 %	J.P. Morgan Securities LLC	3,520	126	12/31/2022
0.00953 %	Riggs Asset Management Company Inc.	3,500	1,325	12/31/2022
0.00861 %	Morgan Stanley & Co. LLC	3,162	1	12/31/2022
0.00613 %	Wells Fargo Advisors	2,250	1,000	12/31/2022
0.00547 %	Cutler Group, LP	2,010	-152	12/31/2022
0.00545 %	Antonetti Capital Management, LLC	2,000	0	12/31/2022
0.00415 %	Morgan Stanley Smith Barney LLC	1,525	-1,553	12/31/2022
0.00313 %	Advisor Group, Inc	1,150	0	12/31/2022
0.00272 %	Cornerstone Planning Group LLC	1,000	1,000	12/31/2022
0.00170 %	Whittier Trust Company	625	0	12/31/2022
0.00147 %	WWM Financial	540	0	12/31/2022
0.00136 %	Kistler-Tiffany Advisors	500	0	12/31/2022
0.00102 %	Independent Financial Partners	375	0	12/31/2022
0.00077 %	BNP Paribas Securities Corp. North America	284	0	12/31/2022
0.00068 %	Harbour Investments, Inc	250	250	12/31/2022
0.00064 %	Wells Fargo Bank, N.A.	235	46	12/31/2022
0.00064 %	BlackRock Financial Management, Inc.	235	0	12/31/2022
0.00023 %	BofA Global Research (US)	86	86	12/31/2022
0.00012 %	RBC Capital Partners	44	44	12/31/2022
0 %	Susquehanna Fundamental Investments, LLC	0	-29,000	12/31/2022
0 %	ExodusPoint Capital Management, LP	0	-10,672	9/30/2021
0 %	Ergoteles Capital	0	-89,800	9/30/2021
0 %	Union Square Park Capital Management, LLC	0	-75,000	6/30/2021
0 %	Squarepoint Capital LLP	0	-38,608	12/31/2021
0 %	Wolverine Trading, LLC	0	-13,173	3/31/2022
0 %	Schonfeld Strategic Advisors LLC	0	-10,800	9/30/2021
0 %	BMO Family Office, LLC	0	-7,610	6/30/2021
0 %	Ikarian Capital LLC	0	-219,109	6/30/2021
0 %	Boothbay Fund Management, LLC	0	-22,832	6/30/2021
0 %	Engineers Gate Manager, L.P.	0	-17,361	9/30/2022
0 %	Trexquant Investment LP	0	-12,151	6/30/2021
0 %	HRT Financial LP	0	-33,463	12/31/2022
0 %	LPL Financial LLC	0	-20,885	9/30/2021
0 %	NEXT Financial Group, Inc.	0	-6,000	12/31/2021
0 %	Focused Wealth Management, Inc.	0	-375	12/31/2021
0 %	PDT Partners, LLC	0	-22,978	6/30/2021
0 %	Barclays Bank PLC	0	-2,359	12/31/2021
0 %	Tibra Equities Europe, Ltd.	0	-109,000	9/30/2021
0 %	Dimensional Fund Advisors, Ltd.	0	-4,701	2/28/2022
0 %	Principal Funds, Inc.	0	-3,654	6/30/2021
0 %	DWS Investments UK Limited	0	-12,696	6/30/2021
0 %	Sigma Planning Corporation	0	-19,300	12/31/2021
0 %	Assenagon Asset Management S.A.	0	-439	6/30/2021
0 %	ProShare Advisors LLC	0	-5,492	6/30/2021
0 %	Relative Value Partners Group, LLC	0	-13,991	6/30/2021
0 %	Penbrook Management, LLC	0	-83,450	6/30/2022
0 %	Phocas Financial Corporation	0	-10,000	12/31/2022
0 %	CAPTRUST Financial Advisors	0	-500	12/31/2021
0 %	GSA Capital Partners LLP	0	-30,880	9/30/2021
0 %	Peak 6 Capital Management, LLC	0	-16,083	3/31/2022
0 %	Neuberger Berman, LLC	0	-37,500	6/30/2021
0 %	Barclays Capital Inc.	0	-2,182	9/30/2021
0 %	Morgan Stanley & Co. International Plc	0	-538	9/30/2021
0 %	Marshall Wace LLP	0	-10,977	9/30/2021
0 %	Millennium Management LLC	0	-191,303	12/31/2022
0 %	LMCG Investments, LLC	0	-3,000	12/31/2021
0 %	Gagnon Securities LLC	0	-47,793	12/31/2021
0 %	ProFund Advisors LLC	0	-429	7/31/2021
0 %	Rafferty Asset Management LLC	0	-22,745	8/31/2021
0 %	Rhumbline Advisers Ltd. Partnership	0	-17,866	6/30/2021
0 %	Segall Bryant & Hamill, LLC	0	-350,659	12/31/2021
0 %	BMO Harris Bank N.A.	0	-2,360	6/30/2021
0 %	Perritt Capital Management, Inc.	0	-30,651	6/30/2021
0 %	Federated Hermes MDTA LLC	0	-1,106	12/31/2022
0 %	Charles Schwab Investment Management, Inc.	0	-41,983	6/30/2021
0 %	Legal & General Investment Management Ltd.	0	-2,180	6/30/2021
0 %	Vaughan Nelson Investment Management, L.P.	0	-689	6/30/2021
0 %	Principal Global Investors (Equity)	0	-3,654	6/30/2021
0 %	DWS Investment Management Americas, Inc.	0	-34,000	9/30/2021

Name	Relationship	Two-week correlation	One-month correlation	Three-Month Correlation	Six-Month Correlation	One Year Correlation	Two-Year Correlation
Bio-Rad Laboratories A	SupplierCustomer	0,60	0,75	0,88	0,92	0,72	-0,29

What values and corporate philosophy does Chembio Diagnostics represent?

Chembio Diagnostics Inc represents values such as innovation, quality, and commitment in the field of diagnostic testing. The company focuses on developing and commercializing rapid point-of-care diagnostic tests for infectious diseases, including HIV, Zika, and Ebola. With a strong corporate philosophy centered around improving patient outcomes and global health, Chembio Diagnostics Inc strives to provide accurate and reliable diagnostic solutions. Their advanced technologies and extensive expertise empower healthcare professionals to make informed decisions for early detection and efficient management of various medical conditions. Through continuous research and development, Chembio Diagnostics Inc remains dedicated to delivering efficient and effective diagnostic solutions to healthcare systems worldwide.

In which countries and regions is Chembio Diagnostics primarily present?

Chembio Diagnostics Inc is primarily present in the United States of America.

What significant milestones has the company Chembio Diagnostics achieved?

Chembio Diagnostics Inc has achieved several significant milestones. The company secured FDA approval for its rapid HIV diagnostic tests, which provided accurate and timely results. Chembio also received Emergency Use Authorization (EUA) for its COVID-19 antibody test, allowing for rapid and reliable detection of antibodies in individuals. Additionally, the company expanded its global reach by partnering with various organizations and securing distribution agreements worldwide. Chembio Diagnostics Inc has consistently demonstrated innovation and commitment to delivering high-quality diagnostic solutions, making it a prominent player in the healthcare industry.

What is the history and background of the company Chembio Diagnostics?

Chembio Diagnostics Inc. is a leading company in the field of point-of-care diagnostic tests. Established in 1985, Chembio has been dedicated to developing innovative, rapid, and reliable testing solutions for infectious diseases. With a strong commitment to global health, the company focuses on creating advanced diagnostic assays that provide accurate results within minutes, enabling better patient care and disease management. Chembio has built a diverse portfolio of products, including rapid tests for HIV, malaria, Zika virus, and syphilis, among others. Over the years, Chembio Diagnostics Inc. has become renowned for its expertise, quality products, and contributions to global healthcare.

Who are the main competitors of Chembio Diagnostics in the market?

Chembio Diagnostics Inc faces competition from various companies in the market. Some of its main competitors include companies like Abbott Laboratories, Bio-Rad Laboratories, and Quidel Corporation. These companies also operate in the diagnostics industry and offer a range of testing solutions and products, often catering to similar customer needs. Chembio Diagnostics Inc strives to differentiate itself through its innovative technology, product quality, and customer service in order to stay competitive in the market.

In which industries is Chembio Diagnostics primarily active?

Chembio Diagnostics Inc is primarily active in the healthcare industry.

What is the business model of Chembio Diagnostics?

Chembio Diagnostics Inc, a leading biotechnology company, operates with a unique business model focusing on the development, manufacturing, and commercialization of diagnostic solutions. The company specializes in point-of-care testing, providing rapid diagnostic tests for infectious diseases, including HIV, Syphilis, and Zika. Chembio's business strategy revolves around developing proprietary technologies and collaborations for market expansion. By leveraging their expertise in immunoassays, microfluidics, and lateral flow technologies, Chembio aims to improve global healthcare outcomes through accurate and affordable diagnostic solutions. With an emphasis on innovation and strategic partnerships, Chembio Diagnostics Inc continues to make significant contributions to the diagnostics industry.

What is the P/E ratio of Chembio Diagnostics 2024?

The Chembio Diagnostics P/E ratio is -0.36.

What is the P/S ratio of Chembio Diagnostics 2024?

The Chembio Diagnostics P/S ratio is 0.4.

What is the AlleAktien quality score of Chembio Diagnostics?

The AlleAktien quality score for Chembio Diagnostics is 4/10.

What is the revenue of Chembio Diagnostics 2024?

The expected Chembio Diagnostics revenue is 36.92 M USD.

How high is the profit of Chembio Diagnostics 2024?

The expected Chembio Diagnostics profit is -40.29 M USD.

What is the business model of Chembio Diagnostics

Chembio Diagnostics Inc. is a company specialized in the development and marketing of rapid tests for infectious diseases. The company is headquartered in Hauppauge, New York, and also operates a production facility in Germany. Chembio Diagnostics' business model is based on offering fast, reliable, and cost-effective diagnostic tests that help doctors and medical professionals detect and treat infectious diseases. The company offers test products for various infections such as HIV, hepatitis C, syphilis, malaria, and dengue fever. Chembio Diagnostics has three main business areas: development, production, and distribution of diagnostic tests. In the development area, the company works intensively on developing new and innovative tests for infectious diseases. The company has its own research and development department that collaborates closely with scientists and industry experts to develop new technologies and products. In the production area, Chembio Diagnostics operates a production facility in Germany where diagnostic tests are manufactured. The company has state-of-the-art technologies and facilities to ensure high quality and production efficiency. The marketing of diagnostic tests is the third business area of Chembio Diagnostics. The company works closely with distributors in different countries to sell its products worldwide. Additionally, the company has distribution agreements with major pharmaceutical companies and medical institutions to promote the spread of its tests. Chembio Diagnostics' products are intended for both medical professionals and patients. The tests are frequently used in medical practices, clinics, and hospitals to diagnose and monitor infections. Additionally, the company also offers rapid tests for field use that can be used by emergency services and doctors in remote areas. Chembio Diagnostics positions itself as a leading provider of rapid tests for infectious diseases and is committed to improving the health of people worldwide. The company continues to invest in research and development to develop innovative products that meet the needs of doctors and patients. Overall, Chembio Diagnostics has built a successful business model based on providing high-quality diagnostic tests for infectious diseases. The company has increased its revenue and global presence and continues its success story.

What is the Chembio Diagnostics dividend?

Chembio Diagnostics pays a dividend of 0 USD distributed over payouts per year.

How often does Chembio Diagnostics pay dividends?

The dividend cannot currently be calculated for Chembio Diagnostics or the company does not pay out a dividend.

What is the Chembio Diagnostics ISIN?

The ISIN of Chembio Diagnostics is US1635722093.

What is the Chembio Diagnostics WKN?

The WKN of Chembio Diagnostics is A1JY4D.

What is the Chembio Diagnostics ticker?

The ticker of Chembio Diagnostics is CEMI.

How much dividend does Chembio Diagnostics pay?

Over the past 12 months, Chembio Diagnostics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Chembio Diagnostics is expected to pay a dividend of 0 USD.

What is the dividend yield of Chembio Diagnostics?

The current dividend yield of Chembio Diagnostics is .

When does Chembio Diagnostics pay dividends?

Chembio Diagnostics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Chembio Diagnostics?

Chembio Diagnostics paid dividends every year for the past 0 years.

What is the dividend of Chembio Diagnostics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Chembio Diagnostics located?

Chembio Diagnostics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Chembio Diagnostics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Chembio Diagnostics from 9/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/18/2024.

When did Chembio Diagnostics pay the last dividend?

The last dividend was paid out on 9/18/2024.

What was the dividend of Chembio Diagnostics in the year 2023?

In the year 2023, Chembio Diagnostics distributed 0 USD as dividends.

In which currency does Chembio Diagnostics pay out the dividend?

The dividends of Chembio Diagnostics are distributed in USD.

Chembio Diagnostics Ticker	Chembio Diagnostics FIGI
CEMIUSD:XB	BBG00K03RKX8
CEMIUSD:XS	BBG00K03RLC9

2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023e	2024e	2025e
0	3	3	6	9	11	13	16	19	25	29	27	24	17	24	34	34	32	47	49	38	36	35
-	-	-	100.00	50.00	22.22	18.18	23.08	18.75	31.58	16.00	-6.90	-11.11	-29.17	41.18	41.67	-	-5.88	46.88	4.26	-22.45	-5.26	-2.78
-	-	33.33	16.67	22.22	27.27	38.46	50.00	47.37	40.00	41.38	37.04	41.67	47.06	45.83	32.35	35.29	25.00	27.66	20.41	-	-	-
0	0	1	1	2	3	5	8	9	10	12	10	10	8	11	11	12	8	13	10	0	0	0
0	-3	-3	-4	-2	-2	0	2	1	1	1	-1	-3	-7	-6	-7	-12	-21	-24	-20	-35	-26	-19
-	-100.00	-100.00	-66.67	-22.22	-18.18	-	12.50	5.26	4.00	3.45	-3.70	-12.50	-41.18	-25.00	-20.59	-35.29	-65.63	-51.06	-40.82	-92.11	-72.22	-54.29
0	-5	-6	-8	-8	-1	0	2	6	0	0	-1	-2	-13	-6	-7	-13	-25	-33	-23	-47	-40	-34
-	-	20.00	33.33	-	-87.50	-	-	200.00	-	-	-	100.00	550.00	-53.85	16.67	85.71	92.31	32.00	-30.30	104.35	-14.89	-15.00
2.26	0.75	0.96	1.29	1.83	7.66	9.38	8.87	8.56	8.61	9.52	9.53	9.63	10.62	12.3	14.43	16.95	19.09	24.3	32.27	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Own the gold standard ✨ in financial data & analytics fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Price

Price

TickerCEMI

ISINUS1635722093

WKNA1JY4D

Chembio Diagnostics stock price

Price

Overview

Intraday Feature

Total Return and Relative Price Change

Interpretation and Investment

Chembio Diagnostics Stock Price History

Chembio Diagnostics Revenue, EBIT, Net Income US1635722093 · A1JY4D

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Yearly Analysis and Comparisons

Utilizing Expectations for Investment

Investment Insights

Chembio Diagnostics Revenue, EBIT and net profit per share

Chembio Diagnostics Income Statement, Balance Sheet, Cash Flow Statement

Keystats

Revenue and Growth

Gross Margin

EBIT and EBIT Margin

Income and Growth

Shares Outstanding

Interpreting Year to Year Comparison

Expectations and Predictions

Balance Sheet

Understanding the Balance Sheet

Assets

Liabilities

Equity

Year-to-Year Analysis

Interpreting the Data

Chembio Diagnostics stock margins US1635722093 · A1JY4D

Margin

Understanding Gross Margin

EBIT Margin Analysis

Revenue Margin Insights

Interpreting Expectations

Comparative Analysis

Chembio Diagnostics Margin History

Chembio Diagnostics Stock Sales Revenue, EBIT, Earnings per Share US1635722093 · A1JY4D

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

Chembio Diagnostics Revenue, EBIT and net profit per share

Chembio Diagnostics business model

Chembio Diagnostics SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

Chembio Diagnostics Revenue by Segment US1635722093 · A1JY4D

Revenue by Segment

Overview of Revenue by Segment

Interpretation and Use

Investment Strategy

Chembio Diagnostics Revenue by Segment

Chembio Diagnostics Revenue by Region US1635722093 · A1JY4D

Revenue by Segment

Overview of Revenue by Region

Interpretation and Usage

Investment Strategy

Chembio Diagnostics Revenue by Segment

Chembio Diagnostics Eulerpool Fair Value

Fair Value

Understanding Fair Value

Income-Based Fair Value

Revenue-Based Fair Value

Dividend-Based Fair Value

Expectations and Forecasts

Comparative Analysis

Chembio Diagnostics historical P/E ratio, EBIT, and P/S ratio.

Chembio Diagnostics shares outstanding US1635722093 · A1JY4D

Revenue, EBIT and Earnings per share

Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Ticker
CEMI

ISIN
US1635722093

WKN
A1JY4D